24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Generics
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
12:00
Unemployment is near a record low but more university graduates are looking for work
11:53
Foreign airlines are returning to Israel. Can Ben Gurion handle them?
11:45
Israeli company unveils satellite with 25 cm resolution and AI processing in orbit
10:36
How the US found and rescued an airman hiding in the Iranian mountains
More stories
Buzz
Most popular
Daily
Weekly
1
She sold her startup to Salesforce. Then she had four kids and started another one.
2
Meta loses its $1.5 billion AI recruit less than a year after hiring him
3
Security breach hits Revolut amid Israeli 'lean bank' license push
4
What Nebius really bought when it bought Tavily
5
What made Anthropic walk away from the $6 billion Decart deal?
More news
Generics
6 stories about Generics
Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself
11.11.19
|
Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18
|
Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Goldman Sachs Sees 16% Upside in Teva Stock
26.06.18
|
Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
In Protest of New Bonus Plan, Teva Sued by Israeli Employees
15.03.18
|
Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
Drugmaker Hikma Appoints Former Teva Executive as CEO
20.02.18
|
Asaf Shalev
The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit